PT  - JOURNAL ARTICLE
AU  - Foster, Charles S.P.
AU  - Rawlinson, William D.
TI  - Rapid spread of a SARS-CoV-2 Delta variant with a frameshift deletion in ORF7a
AID  - 10.1101/2021.08.18.21262089
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.18.21262089
4099  - http://medrxiv.org/content/early/2021/08/21/2021.08.18.21262089.short
4100  - http://medrxiv.org/content/early/2021/08/21/2021.08.18.21262089.full
AB  - Australia is currently experiencing COVID-19 outbreaks from infection with SARS-CoV-2 Delta variants (B.1.617.2, AY.3). Analysis of the index case reveals a sub-consensus level of sequencing reads (∼25%) that support a 17-nucleotide deletion in ORF7a (ORF7aΔ17del). ORF7aΔ17del induces a frameshift mutation in ORF7a, which truncates the peptide and potentially leads to reduced suppression of host restriction factor BST-2/CD317/Tetherin. Despite this, the mutation has rapidly become represented at the consensus level in subsequent cases: approximately 72% of SARS-CoV-2 genomes in the Australian outbreak possess ORF7aΔ17del, and 99.7% (1534/1538) of Delta genomes on GISAID with ORF7aΔ17del originate from the current Australian outbreak (5 August 2021). The global abundance of this mutation might be underestimated given the difficulty of variant calling software correctly calling insertion/deletions (indels), the common inability of phylogenetics software to take indels into account, and the tendency of GISAID to not release submissions that contain a frameshift mutation (unless specifically requested). Overall, the rapid increase of persistent ORF7aΔ17del variants is concerning, and suggests either a chance founder effect with a neutral mutation yet to be purged, or that the ORF7aΔ17del mutation provides a direct selective advantage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding is reported for the present research. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Only open access sequence data via the GISAID platform had been used in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were sourced from the NCBI and GISAID databases, and originate from submissions that were generated (a) in part by the authors, or (b) by authors from other institutions. All appropriate attributions are given following GISAID guidlines in the Supplemental Appendix, including Supplemental Table S1.